Abeona Therapeutics Inc.
ABEO
$6.91
-$0.04-0.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | 5.58% | 10.26% | 2.78% | 89.94% | 57.13% |
| Gross Profit | -4.73% | -18.93% | -10.71% | -121.74% | -78.35% |
| SG&A Expenses | 59.26% | 46.92% | 57.08% | 48.51% | 38.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.08% | 28.92% | 24.20% | 20.19% | 16.76% |
| Operating Income | -31.37% | -37.86% | -33.22% | -29.31% | -26.02% |
| Income Before Tax | 238.32% | 42.36% | -17.62% | -58.84% | -33.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 208.83% | 42.36% | -17.62% | -58.84% | -33.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 208.83% | 42.36% | -17.62% | -58.84% | -33.79% |
| EBIT | -31.37% | -37.86% | -33.22% | -29.31% | -26.02% |
| EBITDA | -32.30% | -39.66% | -35.49% | -32.26% | -29.62% |
| EPS Basic | 148.24% | 72.63% | 30.73% | 9.11% | 30.11% |
| Normalized Basic EPS | 23.73% | 73.10% | 32.23% | 8.36% | 29.65% |
| EPS Diluted | 125.33% | 58.65% | 13.42% | -9.01% | 15.16% |
| Normalized Diluted EPS | 30.48% | 71.86% | 30.70% | 6.70% | 28.29% |
| Average Basic Shares Outstanding | 68.96% | 94.68% | 92.11% | 92.93% | 115.15% |
| Average Diluted Shares Outstanding | 65.21% | 106.38% | 105.24% | 108.27% | 135.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |